Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Celldex Therapeutics, Inc. - Common Stock (NQ:CLDX)

24.54 -0.23 (-0.93%)
Streaming Delayed Price Updated: 2:01 PM EST, Jan 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Celldex Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Forecasting The Future: 5 Analyst Projections For Celldex Therapeutics ↗
 
Via Benzinga
News headline image
What 7 Analyst Ratings Have To Say About Celldex Therapeutics ↗
 
Via Benzinga
Celldex Therapeutics Inc. (NASDAQ: CLDX) Highlighted for Surprising Price Action
Via Investor Brand Network
News headline image
Celldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Top Picks 2024: Celldex Therapeutics, Inc. ↗
Celldex Therapeutics is one of our top picks for the year. With very good data and the financing behind it, now could be the time to take advantage of the pullback in shares to initiate and/or add to... 
Via Talk Markets
News headline image
Top 4 Health Care Stocks That May Crash This Month ↗
As of Dec. 20, 2023, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. 
Via Benzinga
News headline image
Celldex Therapeutics to Present at 6th Annual Evercore ISI HealthCONx Conference
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biotech Breakthroughs: 3 Revolutionary Stocks Redefining Healthcare ↗
Are you looking for biotech breakthrough stocks? Here are three revolutionary stocks redefining healthcare. 
Via InvestorPlace
News headline image
Why Celldex Therapeutics (CLDX) Stock Is Getting Hammered ↗
Celldex Therapeutics, Inc. (NASDAQ: CLDX) shares are trading lower after the company announced a proposed public offering of 7.425 million shares at $27 per share. 
Via Benzinga
News headline image
Celldex Therapeutics Announces Pricing of Public Offering of Common Stock
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Therapeutics Announces Proposed Public Offering of Common Stock
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why Celldex Therapeutics Blasted 13% Higher on Monday ↗
The biotech's CSU treatment advanced in the laboratory. 
Via The Motley Fool
News headline image
Celldex Makes A Bullish Move As It Looks To Take On Regeneron, Sanofi ↗
The company is looking to take on Regeneron and Sanofi's Dupixent in skin diseases. 
Via Investor's Business Daily
News headline image
Why Bluegreen Vacations Shares Are Trading Higher By Around 105%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Gainers Carbon Revolution Public Limited (NASDAQ: CREV) shares jumped 396.2% to $145.49 after gaining 100% on Friday. The company’s stock began trading on Friday following merger with Twin Ridge... 
Via Benzinga
News headline image
Why Is Inflammation Disease-Focused Celldex Therapeutics Stock Trading Higher Today? ↗
Celldex Therapeutics Inc (NASDAQ: CLDX) released topline results from its Phase 2 trial of barzolvolimab in patients with moderate to severe chronic spontaneous urticaria (CSU) refractory to... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Celldex Therapeutics Announces Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Therapeutics Presents Positive Data from Prurigo Nodularis Phase 1b Study Demonstrating Meaningful Reduction in Itch and Skin Clearing with Single Dose 3.0 mg/kg Barzolvolimab
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1b Results in Prurigo Nodularis at 12th World Congress on Itch (WCI) 2023
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Therapeutics to Present at Cantor Global Healthcare Conference
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Wall Street's Top 10 Stock Calls This Week - Sunday, Aug. 27 ↗
Via Talk Markets
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 22, 2023 ↗
 
Via Benzinga
News headline image
Celldex Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Therapeutics Presents Positive Data from Barzolvolimab Chronic Urticaria Program at EAACI 2023
From Celldex Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.